

FluCov Influenza Activity Report #14

26 February 2024


Take home: elevated but decreasing influenza activity in the Northern Hemisphere

- **North America and Europe:** Although decreasing, influenza activity in the United States remains elevated with moderate to high activity in many states. In Europe, a mixed activity pattern was observed. Influenza activity decreased in many countries (Denmark, France, Germany, Italy, Spain), but activity continues to vary from very low activity in Italy and Spain to high activity in France, Germany and the Netherlands.
- **Asia:** Influenza overall positivity rate continued to decrease in China, but remained elevated, with moderate activity reported overall.
- **Circulating virus:** While A/H3 and B/Victoria have predominated globally and in China, A/H1N1pdm09 has dominated circulation in most of the Northern Hemisphere. Presently, there are no documented cases of B-Yamagata
- **Vaccine match:** Early indicators in the US suggest good vaccine match. France reports good match with A/H1N1pdm09, but mismatch in some percentage of A/H3 viruses.
- **Influenza Viruses of Pandemic Potential:** A case of avian influenza A(H5N1), 17-year-old girl with symptoms, was confirmed in Cambodia on 20 Feb 2024 (promed). On 23 Feb 2024, a case of avian influenza A(H9N2) was confirmed in a 22-month-old girl in Hong; the girl is no longer symptomatic (promed).
- **COVID hospitalizations:** continue to decrease in England, EU and the US, after a peak around the end of 2023.

Positive Influenza tests (%)


Note: the positivity rate graph for the UK was last updated week 06/2024.

— Season 2023/2024
 — Season 2022/2023
 — Season 2021/2022
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



Weekly COVID-19 hospital admissions

(England, EU/EEA, US – admissions/100,000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen.

Data sources & details

US: FluView (Clinical Laboratories)

DK: WHO FluNET (non-sentinel)

Other EU countries: ERVISS

All others: WHO FluNet (sentinel)

COVID: US (Department of Health and Human Services) EU (ERVISS), England (UKHSA)

A Nivel publication

FluCov team: Bronke Boudewijns, Susanne Heemskerk, Marco Del Riccio, Saverio Caini, John Paget.

[FluCov Influenza Activity Report #14: 26 February 2024](#). Netherlands, Utrecht: Nivel, 2024

Websites for more information

Project Website: <https://www.nivel.nl/en/flucoV>

FluCoV Dashboard: <https://www.nivel.nl/en/flucoV-dashboard>

Funding

The Nivel FluCov project is funded by Sanofi
